<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vitamin D2 (ergocalciferol): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vitamin D2 (ergocalciferol): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vitamin D2 (ergocalciferol): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10150" href="/d/html/10150.html" rel="external">see "Vitamin D2 (ergocalciferol): Drug information"</a> and <a class="drug drug_patient" data-topicid="12426" href="/d/html/12426.html" rel="external">see "Vitamin D2 (ergocalciferol): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F166127"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Calcidol [OTC];</li>
<li>Calciferol [OTC] [DSC];</li>
<li>Drisdol;</li>
<li>Ergocal [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866762"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>D-Forte;</li>
<li>SANDOZ D-Forte</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1058419"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Nutritional Supplement</span>;</li>
<li>
<span class="list-set-name">Vitamin D Analog</span>;</li>
<li>
<span class="list-set-name">Vitamin, Fat Soluble</span></li></ul></div>
<div class="block don drugH1Div" id="F53462441"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> 1 mcg = 40 USP units.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Adequate Intake (AI):</b> Oral: 400 units/day (10 mcg/day) (IOM 2011).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a45dcd6-9236-4798-b536-057ca39dacf3">Vitamin D deficiency, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vitamin D deficiency, prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Premature neonates:</p>
<p style="text-indent:-2em;margin-left:6em;">Birthweight ≤1.5 kg: Oral: Initial: 200 units (5 mcg) daily; increase to 400 units (10 mcg) daily when weight &gt;1.5 to 2 kg and tolerating full enteral nutrition (AAP [Abrams 2013]); some experts recommended higher doses of 800 to 1,000 units (20 to 25 mcg) daily for stable growing preterm neonates weighing 1 to 1.8 kg (ESPGHAN [Agostoni 2010]).</p>
<p style="text-indent:-2em;margin-left:6em;">Birthweight &gt;1.5 kg: Oral: 400 units (10 mcg) daily when tolerating full enteral nutrition (AAP [Abrams 2013]); some experts recommended higher doses of 800 to 1,000 units (20 to 25 mcg) daily for stable growing preterm neonates up to 1.8 kg (ESPGHAN [Agostoni 2010]).</p>
<p style="text-indent:-2em;margin-left:4em;">Full-term neonates: Breast-fed (fully or partially): Oral: 400 units (10 mcg) daily beginning in the first few days of life; continue supplementation unless infant is transitioned to full formula intake (AAP [Golden 2014]; Abrams 2020).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d7278f3d-2f6e-4154-9b1e-1f8fd3076ce8">Vitamin D deficiency, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vitamin D deficiency (severe, symptomatic), treatment:</b> Full-term neonates: Oral: 2,000 units (50 mcg) daily for 6 weeks to achieve a serum 25(OH)D level &gt;20 ng/mL; followed by a maintenance dose of 400 to 1,000 units (10 to 25 mcg) daily. Monitor vitamin D status closely; treatment should also include calcium supplementation (AAP [Golden 2014]; Munns 2016). A lower dose of 1,000 units (25 mcg) daily has also been recommended (AAP [Misra 2008]).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F166147"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> 1 mcg = 40 USP units.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="19750dd2-98a1-45fc-8bb7-e3dde2a3a1cb">Hypoparathyroidism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoparathyroidism:</b> Infants, Children, and Adolescents: Oral: 50,000 to 200,000 units (1,250 to 5,000 mcg) daily with calcium supplements.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a45dcd6-9236-4798-b536-057ca39dacf3">Vitamin D deficiency, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vitamin D deficiency, prevention (eg, Rickets prevention)</b> (AAP [Golden 2014]; Abrams 2020; Munns 2016):</p>
<p style="text-indent:-2em;margin-left:4em;">Breastfed infants (fully or partially): Oral: 400 units (10 mcg) daily beginning in the first few days of life; continue supplementation unless infant is transitioned to full formula intake.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents without adequate intake: Oral: 600 units (15 mcg) daily. <b>Note:</b> Children with increased risk of vitamin D deficiency (chronic fat malabsorption, maintained on chronic antiseizure medications) may require higher doses. Use laboratory testing [25(OH)D, PTH, bone mineral status] to evaluate.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d7278f3d-2f6e-4154-9b1e-1f8fd3076ce8">Vitamin D deficiency, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vitamin D deficiency (severe, symptomatic), treatment:</b>
<b>Note:</b> Treatment should also include calcium; some patients with chronic fat malabsorption, obesity, or who are maintained on chronic antiseizure medications, glucocorticoids, HIV medications, or antifungals may require higher doses of ergocalciferol (AAP [Golden 2014]); monitor vitamin D status closely:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: Oral: 2,000 units (50 mcg) daily for 6 weeks to achieve a serum 25(OH)D level &gt;20 ng/mL; followed by a maintenance dose of 400 to 1,000 units (10 to 25 mcg) daily. <b>Note:</b> For patients at high risk of fractures a serum 25(OH)D level &gt;30 ng/mL has been suggested (AAP [Golden 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: 2,000 units (50 mcg) daily for 6 to 8 weeks to achieve a serum 25(OH)D level &gt;20 ng/mL; followed by a maintenance dose of 600 to 1,000 units (15 to 25 mcg) daily. <b>Note:</b> For patients at high risk of fractures a serum 25(OH)D level &gt;30 ng/mL has been suggested (AAP [Golden 2014]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eff2c025-0f2a-4a4b-bb06-7bd0b0256e8d">Vitamin D insufficiency or deficiency associated with CKD; serum 25 hydroxyvitamin D level &lt;30 ng/mL</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vitamin D insufficiency or deficiency associated with CKD (stages 2 to 5, 5D); serum 25 hydroxyvitamin D (25[OH]D) level &lt;30 ng/mL:</b> (K/DOQI Guidelines 2009):</p>
<p style="text-indent:-2em;margin-left:4em;">Serum 25(OH)D level 16 to 30 ng/mL: Infants, Children, and Adolescents: Oral: 2,000 units (50 mcg) daily for 3 months or 50,000 units (1,250 mcg) every month for 3 months.</p>
<p style="text-indent:-2em;margin-left:4em;">Serum 25(OH)D level 5 to 15 ng/mL: Infants, Children, and Adolescents: Oral: 4,000 units (100 mcg) daily for 12 weeks or 50,000 units (1,250 mcg) every other week for 12 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">Serum 25(OH)D level &lt;5 ng/mL: Infants, Children, and Adolescents: Oral: 8,000 units (200 mcg) daily for 4 weeks then 4,000 units (100 mcg) daily for 2 months for total therapy of 3 months or 50,000 units (1,250 mcg) <b>weekly</b> for 4 weeks followed by 50,000 units (1,250 mcg) 2 times monthly for a total therapy of 3 months.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance dose [once repletion accomplished; serum 25(OH)D level &gt;30 ng/mL]: Infants, Children, and Adolescents: Oral: 200 to 1,000 units (5 to 25 mcg) daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e4202a37-b62f-40ee-9d63-1df548d9fd88">Rickets</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rickets:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Nutritional rickets, treatment: </i></b>Limited data available (Munns 2016): Administer in combination with calcium supplementation:</p>
<p style="text-indent:-2em;margin-left:6em;">Daily therapy (preferred):</p>
<p style="text-indent:-2em;margin-left:8em;">Infants: Oral: 2,000 units (50 mcg) daily for ≥3 months, followed by maintenance dose of 400 units (10 mcg) daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Children: Oral: 3,000 to 6,000 units (75 to 150 mcg) daily for ≥3 months, followed by maintenance dose of 600 units (15 mcg) daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: Oral: 6,000 units (150 mcg) daily for ≥3 months, followed by maintenance dose of 600 units (15 mcg) daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Single-dose therapy: <b>Note:</b> While ergocalciferol can be used, cholecalciferol is the preferred supplement for single-dose therapy due to longer half-life</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥3 months: Oral: 50,000 units (1,250 mcg) once, or in divided doses over several days; after 3 months, initiate maintenance dose of 400 units (10 mcg) daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Children: Oral: 150,000 units (3,750 mcg) once, or in divided doses over several days; after 3 months, initiate maintenance dose of 600 units (15 mcg) daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: Oral: 300,000 units (7,500 mcg) once, or in divided doses over several days; after 3 months, initiate maintenance dose of 600 units (15 mcg) daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51108657"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however, ergocalciferol is not renally eliminated to a significant extent and dosage adjustment is not necessary.</p></div>
<div class="block dohp drugH1Div" id="F51108658"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doa drugH1Div" id="F166131"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10150" href="/d/html/10150.html" rel="external">see "Vitamin D2 (ergocalciferol): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> 1 mcg = 40 units</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6684f5e6-d09f-43ef-a1bd-5ea9171e77f2">Osteoporosis prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis prevention (off-label use):</b>
<b>Oral:</b> Adults ≥50 years of age: 800 to 1,000 units/day (20 to 25 mcg/day) is recommended, through dietary sources and/or supplementation if needed (NOF [Cosman 2014]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="61c617b7-e72d-4186-b702-18c05aeca613">Vitamin D insufficiency/deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vitamin D insufficiency/deficiency (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The optimal serum 25-hydroxyvitamin D (25[OH]D) level has not been established; generally, deficiency is defined as 25(OH)D levels &lt;12 ng/mL (&lt;30 nmol/L), and insufficiency is defined as 25(OH)D levels 12 to &lt;20 ng/mL (30 to &lt;50 nmol/L) (Giustina 2019). Therefore, some experts suggest a target range of 20 to 40 ng/mL (50 to 100 nmol/L) for most patients (Dawson-Hughes 2022). Individualize dose based on patient-specific factors (eg, presence of malabsorption, liver disease, kidney disease) and target 25(OH)D level and ensure adequate calcium intake during therapy (Dawson-Hughes 2022; NOF [Cosman 2014]). The following recommendations are based primarily on expert opinion and clinical experience:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Prevention:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 600 to 1,000 units (15 to 25 mcg) once daily (IOM 2011; NOF [Cosman 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Treatment:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial dosing:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>High-dose therapy:</b> May be preferred in patients with a serum 25(OH)D level &lt;12 ng/mL (&lt;30 nmol/L) or who are symptomatic (eg, bone fracture/pain, muscle weakness), <b>or </b>in patients with concomitant hypocalcemia (Dawson-Hughes 2022; Goltzman 2022; NOF [Cosman 2014]).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 50,000 units (1,250 mcg) once weekly (or equivalent dose administered once daily) for 6 to 12 weeks, then recheck 25(OH)D level; may repeat high-dose therapy if needed to achieve target 25(OH)D level (Dawson-Hughes 2022; Goltzman 2022; NOF [Cosman 2014]).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Low-dose therapy:</b> May be preferred in patients with a serum 25(OH)D level 12 to &lt;20 ng/mL (30 to &lt;50 nmol/L) without symptoms or concomitant hypocalcemia (Dawson-Hughes 2022).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 800 to 1,000 units (20 to 25 mcg) once daily for ~3 to 4 months; may adjust dose if needed every 3 to 4 months based on 25(OH)D level. Some experts suggest modest dose increases (eg, to 2,000 units [50 mcg] once daily) if serum 25(OH)D levels have substantially increased but remain below target or switching to high-dose therapy if serum 25(OH)D levels remain substantially below target (Dawson-Hughes 2022).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dosing:</i>
<b>Oral:</b> Once target 25(OH)D level is achieved, continue at a maintenance dose of 600 to 2,000 units (15 to 50 mcg) once daily (Dawson-Hughes 2022; NOF [Cosman 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Special populations (eg, obesity, patients on medications known to affect vitamin D metabolism, malabsorption, gastrectomy):</b> Higher doses or longer durations may be necessary for adequate replacement. In patients with malabsorption when target 25(OH)D levels cannot be maintained with ergocalciferol, consider switching to hydroxylated vitamin D metabolites (eg, calcitriol) (Brandi 2013; Dawson-Hughes 2022).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991604"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">In patients with chronic kidney disease (CKD) G3a to G5D, Kidney Disease Improving Global Outcomes guidelines recommend correcting vitamin D deficiency and insufficiency with treatment strategies recommended for patients without kidney impairment. In patients with CKD G4 to G5 with severe and progressive hyperparathyroidism despite correction of modifiable factors (eg, hyperphosphatemia, vitamin D deficiency), calcitriol or vitamin D analogs are suggested (KDIGO 2017).</p></div>
<div class="block doha drugH1Div" id="F50988824"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F166101"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Endocrine &amp; metabolic: Hypervitaminosis D</p></div>
<div class="block coi drugH1Div" id="F166116"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypercalcemia; malabsorption syndrome; abnormal sensitivity to the toxic effects of vitamin D; hypervitaminosis D.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although the manufacturer's labeling lists use in malabsorption syndrome as contraindicated, when dosed appropriately, ergocalciferol may be used in these patients (AACE/ACE [Camacho 2020]; Dawson-Hughes 2022).</p></div>
<div class="block war drugH1Div" id="F166098"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Vitamin D toxicity: May occur with excessive doses; symptoms may include nausea, vomiting, loss of appetite, constipation, dehydration, fatigue, irritability, confusion, weakness, and/or weight loss. Effects of vitamin D can last ≥2 months after therapy is discontinued.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperphosphatemia: Normal serum phosphorous concentrations must be maintained in patients treated for hyperphosphatemia to prevent metastatic calcification.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Oral solutions may contain propylene glycol; toxicities may occur if large doses of vitamin D are required. Alternate dosage forms/products should be used (Misra 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">• Tartrazine: Products may contain tartrazine, which may cause allergic reactions in certain individuals.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878446"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F166109"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Drisdol: 1250 mcg (50000 unit) [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #5 (tartrazine), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ergocal: 62.5 mcg (2500 unit) [DSC] [gluten free; contains fd&amp;c blue #1 (brill blue) aluminum lake, gelatin (bovine), quinoline yellow (d&amp;c yellow #10), soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1250 mcg (50000 unit)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Calcidol: 200 mcg/mL (8000 unit/mL) (60 mL) [alcohol free, dye free, gluten free, lactose free, sugar free; contains propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Calciferol: 200 mcg/mL (8000 unit/mL) (60 mL [DSC]) [contains propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mcg/mL (8000 unit/mL) (60 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mcg (400 unit), 50 mcg (2000 unit)</p></div>
<div class="block geq drugH1Div" id="F166094"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F5686151"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Drisdol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.25 MG(50000 UT) (per each): $3.49</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Ergocalciferol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.25 MG(50000 UT) (per each): $0.72</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Calcidol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg/mL (per mL): $1.66</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ergocalciferol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg/mL (per mL): $0.59 - $1.67</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866763"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1250 mcg (50000 unit)</p></div>
<div class="block adip drugH1Div" id="F53566329"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">1.25 mg ergocalciferol provides 50,000 units of vitamin D activity; 1 drop of 8000 units/mL = 200 units (40 drops = 1 mL)</p></div>
<div class="block admp drugH1Div" id="F52612708"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to meals; for oral liquid, administer with an accurate measuring device; do not use a household teaspoon (overdosage may occur).</p></div>
<div class="block sts drugH1Div" id="F166125"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 15°C to 30°C (59°F to 86°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53566713"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of refractory rickets, familial hypophosphatemia, and hypoparathyroidism (All indications: Capsules: FDA approved in pediatric patients [age not specified] and adults): Vitamin D dietary supplement (OTC product: Oral solution and Tablets: FDA approved in all ages); has also been used to treat vitamin D deficiency and insufficiency in patients with chronic kidney disease (CKD)</p></div>
<div class="block mst drugH1Div" id="F166164"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Calciferol may be confused with calcifediol, calcitriol</p>
<p style="text-indent:-2em;margin-left:4em;">Drisdol may be confused with Drysol</p>
<p style="text-indent:-2em;margin-left:4em;">Ergocalciferol may be confused with alfacalcidol, cholecalciferol</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Liquid vitamin D preparations have the potential for dosing errors when administered to infants. Droppers should be clearly marked to easily provide 400 units. For products intended for infants, the FDA recommends that accompanying droppers deliver no more than 400 units per dose.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299278"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F166103"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: Serum Phosphate Level-Altering Agents may diminish the therapeutic effect of Erdafitinib.  Management: Avoid coadministration of serum phosphate level-altering agents with erdafitinib before initial dose increase period based on serum phosphate levels (Days 14 to 21).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the absorption of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or 2 hours after the administration of orlistat. Avoid concomitant administration due to the risk of impaired vitamin absorption.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.<i> Risk X: Avoid combination</i></p></div>
<div class="block dic drugH1Div" id="F5075487"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Vitamin D is found in egg yolks, fatty fish, fortified milk, fortified cereal, and infant formulas; it is also produced by exposure to sunlight (IOM 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary Reference Intake for Vitamin D (IOM 2011):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants 0 to 12 months: Adequate intake: 10 mcg/day (400 units/day)</p>
<p style="text-indent:-2em;margin-left:4em;">1 to 70 years: RDA: 15 mcg/day (600 units/day)</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;70 years: RDA: 20 mcg/day (800 units/day)</p>
<p style="text-indent:-2em;margin-left:4em;">Pregnancy/Lactating: RDA: 15 mcg/day (600 units/day)</p></div>
<div class="block pri drugH1Div" id="F5075482"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">The ergocalciferol (vitamin D<sub>2</sub>) metabolite, 25(OH)D, crosses the placenta; maternal serum concentrations correlate with fetal concentrations at birth (Misra 2008; Wagner 2008).</p>
<p style="text-indent:0em;margin-top:2em;">Vitamin D deficiency in a pregnant woman may lead to a vitamin D deficiency in the neonate (Misra 2008; Wagner 2008). Serum 25(OH)D concentrations should be measured in pregnant women considered to be at increased risk of deficiency (ACOG 2011). The amount of vitamin D contained in prenatal vitamins may not be adequate to treat a deficiency during pregnancy; although larger doses may be needed, current guidelines recommend a total of 1000 to 2000 units/day until more safety data is available (ACOG 2011). In women not at risk for deficiency, doses larger than the RDA should be avoided during pregnancy (ACOG 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal vitamin D requirements are the same for breastfeeding and nonbreastfeeding females (IOM 2011). The maternal dose of vitamin D needed to provide the infant with an adequate amount of vitamin D is still under study (Wagner 2008)</p></div>
<div class="block mopp drugH1Div" id="F53566712"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Children at increased risk of vitamin D deficiency (chronic fat malabsorption, chronic antiseizure medication use) require serum 25(OH)D, PTH, and bone-mineral status to evaluate. If vitamin D supplement is required, then 25(OH)D levels should be repeated at 3-month intervals until normal. PTH and bone mineral-status should be monitored every 6 months until normal.</p>
<p style="text-indent:0em;margin-top:2em;">Chronic kidney disease: Monitor serum 25(OH)D, corrected total calcium and phosphorus levels 1 month following initiation of therapy, every 3 months during therapy and with any vitamin D dose change; alkaline phosphatase, BUN, bone x-ray (hypoparathyroidism) </p></div>
<div class="block rerp drugH1Div" id="F53566267"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D status may be determined by serum 25(OH) D levels (Misra 2008):</p>
<p style="text-indent:-2em;margin-left:4em;">Severe deficiency: ≤5 ng/mL (12.5 nmol/L)</p>
<p style="text-indent:-2em;margin-left:4em;">Deficiency: 15 ng/mL (37.5 nmol/L)</p>
<p style="text-indent:-2em;margin-left:4em;">Insufficiency: 15 to 20 ng/mL (37.5 to 50 nmol/L)</p>
<p style="text-indent:-2em;margin-left:4em;">Sufficiency: 20 to 100 ng/mL (50 to 250 nmol/L)*</p>
<p style="text-indent:-2em;margin-left:4em;">Excess: &gt;100 ng/mL (250 nmol/L)**</p>
<p style="text-indent:-2em;margin-left:4em;">Intoxication: 150 ng/mL (375 nmol/L)</p>
<p style="text-indent:-2em;margin-left:2em;">*Based on adult data a level of &gt;32 ng/mL (80 nmol/L) is desirable</p>
<p style="text-indent:-2em;margin-left:2em;">**Arbitrary designation</p>
<p style="text-indent:-2em;margin-left:2em;">Target serum 25(OH) D: &gt;30 ng/mL</p></div>
<div class="block pha drugH1Div" id="F166097"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ergocalciferol (vitamin D<sub>2</sub>) is a provitamin. The active metabolite, 1,25-dihydroxyvitamin D (calcitriol), stimulates calcium and phosphate absorption from the small intestine, promotes secretion of calcium from bone to blood; promotes renal tubule phosphate resorption.</p></div>
<div class="block phk drugH1Div" id="F166115"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 10 to 24 hours; Maximum effect: ~1 month following daily doses</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Absorbed in the small intestine; fat soluble; requires bile (IOM 2011)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Inactive until hydroxylated hepatically to 25-hydroxyvitamin D [25(OH)D; calcifediol] then renally to the active metabolite 1,25-dihydroxyvitamin D (calcitriol)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life, circulating: 25(OH)D: 2 to 3 weeks; 1,25-dihydroxyvitamin D ~4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (IOM 2011)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F166120"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">D forte</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ostelin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ergocalciferol d2 | Vitamina d2</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Vitamin D2</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Calciferol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Vitamina d</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Devarol | Ossofortin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Calciferol | Rx d2</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ostelin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Calciferol | Mega-Cal</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Drisdol | Vitamin D2</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ostelin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Calciferol | Vitamin d</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Sterogyl</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Calciferol | Vitamin d</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Vd4 | Vitamina d2</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Afi-d2 forte</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Calciferol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Kalcyfediol | Vitamin d</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Drisdol | Vitamin d | Vitamin D2 | Vitamina d</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Calciferol Biotika Forte</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Calciferol | Calciferol bbp</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Calciferol | Vitamin D2</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Vitamina d</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Calciferol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-23629620">
<a name="23629620"></a>Abrams SA, Committee on Nutrition. Calcium and vitamin D requirements of enterally fed preterm infants. <i>Pediatrics</i>. 2013;131(5):e1676-1683.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/23629620/pubmed" id="23629620" target="_blank">23629620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33232955">
<a name="33232955"></a>Abrams SA. Vitamin D in preterm and full-term infants. <i>Ann Nutr Metab</i>. 2020;76(suppl 2):6-14. doi:10.1159/000508421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/33232955/pubmed" id="33232955" target="_blank">33232955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21691184">
<a name="21691184"></a>ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 495: Vitamin D: Screening and supplementation during pregnancy. <i>Obstet Gynecol</i>. 2011;118(1):197-198. doi:10.1097/AOG.0b013e318227f06b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/21691184/pubmed" id="21691184" target="_blank">21691184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19881390">
<a name="19881390"></a>Agostoni C, Buonocore G, Carnielli VP, et al. Enteral nutrient supply for preterm infants: commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2010;50(1):85-91. doi:10.1097/MPG.0b013e3181adaee0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/19881390/pubmed" id="19881390" target="_blank">19881390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26943719">
<a name="26943719"></a>Brandi ML, Bilezikian JP, Shoback D, et al. Management of hypoparathyroidism: summary statement and guidelines. <i>J Clin Endocrinol Metab</i>. 2016;101(6):2273-2283. doi:10.1210/jc.2015-3907<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/26943719/pubmed" id="26943719" target="_blank">26943719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24020910">
<a name="24020910"></a>Brandi ML, Minisola S. Calcidiol [25(OH)D3]: from diagnostic marker to therapeutical agent. <i>Curr Med Res Opin</i>. 2013;29(11):1565-1572. doi:10.1185/03007995.2013.838549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/24020910/pubmed" id="24020910" target="_blank">24020910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32427503">
<a name="32427503"></a>Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. <i>Endocr Pract</i>. 2020;26(suppl 1):S1-S46. doi:10.4158/GL-2020-0524SUPPL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/32427503/pubmed" id="32427503" target="_blank">32427503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21538511">
<a name="21538511"></a>Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia [published correction appears in <i>J Bone Miner Res</i>. 2015;30(2):394]. <i>J Bone Miner Res</i>. 2011;26(7):1381-1388. doi:10.1002/jbmr.340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/21538511/pubmed" id="21538511" target="_blank">21538511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25182228">
<a name="25182228"></a>Cosman F, de Beur SJ, LeBoff MS, et al; National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381. doi:10.1007/s00198-014-2794-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/25182228/pubmed" id="25182228" target="_blank">25182228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dawson-Hughes.2018">
<a name="Dawson-Hughes.2018"></a>Dawson-Hughes B. Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 20, 2022.</div>
</li>
<li>
<div class="reference">
                  Drisdol (ergocalciferol) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; July 2018.</div>
</li>
<li>
<div class="reference">
                  Drisdol capsule (ergocalciferol) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; May 2012.</div>
</li>
<li>
<div class="reference">
                  Drisdol solution (ergocalciferol) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; June 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30907953">
<a name="30907953"></a>Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1595-1622. doi:10.1210/jc.2019-00221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/30907953/pubmed" id="30907953" target="_blank">30907953</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  FDA consumer update. Infant overdose risk with liquid vitamin D. June 15, 2010. <a href="https://www.fda.gov/forconsumers/consumerupdates/ucm214343.htm" target="_blank">https://www.fda.gov/forconsumers/consumerupdates/ucm214343.htm</a>. Accessed March 11, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Folsom.2017">
<a name="Folsom.2017"></a>Folsom LJ, DiMeglio LA. Recommendations released on prevention, management of rickets. <i>AAP News</i>. http://www.aappublications.org/news/2017/02/10/Rickets021017. Published February 10, 2017. Accessed October 19, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30383226">
<a name="30383226"></a>Giustina A, Adler RA, Binkley N, et al. Controversies in vitamin D: summary statement from an international conference. <i>J Clin Endocrinol Metab.</i> 2019;104(2):234-240. doi:10.1210/jc.2018-01414<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/30383226/pubmed" id="30383226" target="_blank">30383226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25266429">
<a name="25266429"></a>Golden NH, Abrams SA; Committee on Nutrition. Optimizing bone health in children and adolescents. <i>Pediatrics</i>. 2014;134(4):e1229-e1243. doi:10.1542/peds.2014-2173<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/25266429/pubmed" id="25266429" target="_blank">25266429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goltzman.1">
<a name="Goltzman.1"></a>Goltzman D. Treatment of hypocalcemia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10690566">
<a name="10690566"></a>Greer FR. Vitamin metabolism and requirements in the micropremie. <i>Clin Perinatol</i>. 2000;27(1):95-118, vi.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/10690566/pubmed" id="10690566" target="_blank">10690566</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Institute of Medicine (IOM). <i>Dietary Reference Intakes for Calcium and Vitamin D.</i> Washington, DC: The National Academies Press; 2011.</div>
</li>
<li>
<div class="reference">
                  KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Guideline 7. Prevention and treatment of vitamin D insufficiency and vitamin D deficiency in CKD patients. http://kidneyfoundation.cachefly.net/professionals/KDOQI/guidelines_bone/guide7.htm. Published 2003. Accessed October 31, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19231749">
<a name="19231749"></a>KDOQI Work Group. KDOQI clinical practice guideline for nutrition in children with CKD: 2008 update. Executive summary. <i>Am J Kidney Dis</i>. 2009;53(3)(suppl 2):S11-S104. doi:10.1053/j.ajkd.2008.11.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/19231749/pubmed" id="19231749" target="_blank">19231749</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, Part 4. Definition and Classification of Stages of Chronic Kidney Disease. <i>Am J Kidney Dis</i>. 2002;39(2)(suppl 1):46-75.</div>
</li>
<li>
<div class="reference">
                  Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. <i>Kidney Inter</i>. 2013;3:1-150.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2017">
<a name="KDIGO.2017"></a>Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). <i>Kidney Int Suppl</i>. 2017;7(1):1-59. https://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf. Accessed October 25, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-McKeever.2017">
<a name="McKeever.2017"></a>McKeever L. Vitamins and Trace Elements. In: Mueller CM, ed. <i>A.S.P.E.N. Adult Nutrition Support Core Curriculum. </i>3rd edition. Silver Spring, MD: American Society for Parenteral and Enteral Nutrition; 2017:146. http://www.nutritioncare.org/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18676559">
<a name="18676559"></a>Misra M, Pacaud D, Petryk A, et al. Vitamin D Deficiency in Children and Its Management: Review of Current Knowledge and Recommendations. <i>Pediatrics</i>. 2008;122(2):398-417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/18676559/pubmed" id="18676559" target="_blank">18676559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26745253">
<a name="26745253"></a>Munns CF, Shaw N, Kiely M, et al. Global consensus recommendations on prevention and management of nutritional rickets. <i>J Clin Endocrinol Metab</i>. 2016;101(2):394-415. doi:10.1210/jc.2015-2175<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/26745253/pubmed" id="26745253" target="_blank">26745253</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Osteoporosis Foundation (NOF). Clinician’s guide to prevention and treatment of osteoporosis. Washington, DC, 2014. http://nof.org/hcp/resources/913
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14580225">
<a name="14580225"></a>Sanchez CP. Secondary Hyperparathyroidism in Children With Chronic Renal Failure: Pathogenesis and Treatment. <i>Paediatr Drugs</i>. 2003;5(11):763-776.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/14580225/pubmed" id="14580225" target="_blank">14580225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20460620">
<a name="20460620"></a>Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial [published correction appears in <i>JAMA</i>. 2010;303(23):2357]. <i>JAMA</i>. 2010;303(18):1815-1822. doi:10.1001/jama.2010.594<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/20460620/pubmed" id="20460620" target="_blank">20460620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28323044">
<a name="28323044"></a>Smith LM, Gallagher JC, Suiter C. Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: A randomized clinical trial. <i>J Steroid Biochem Mol Biol</i>. 2017;173:317-322. doi:10.1016/j.jsbmb.2017.03.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/28323044/pubmed" id="28323044" target="_blank">28323044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19699370">
<a name="19699370"></a>Stechschulte SA, Kirsner RS, Federman DG. Vitamin D: Bone and Beyond, Rationale and Recommendations for Supplementation. <i>Am J Med</i>. 2009;122(9):793-802.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/19699370/pubmed" id="19699370" target="_blank">19699370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18977996">
<a name="18977996"></a>Wagner CL, Greer FR; American Academy of Pediatrics Section on Breastfeeding; American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. <i>Pediatrics</i>. 2008;122(5):1142-1152. doi:10.1542/peds.2008-1862<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vitamin-d2-ergocalciferol-pediatric-drug-information/abstract-text/18977996/pubmed" id="18977996" target="_blank">18977996</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13274 Version 355.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
